EUCTR2005-005077-29-FR进行中（未招募）不适用
An International, Phase II, Randomized, Double-Blinded, Placebo-Controlled, Multi-Center Study to Assess the Efficacy of ZD6474 (ZACTIMA ) versus Placebo in Subjects with Unresectable Locally Advanced or Metastatic Medullary Thyroid Cancer.
适应症
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 232
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1.Provision of written informed consent
- •2.Female or male aged 18 years and over
- •3.Previously confirmed histological diagnosis of unresectable, locally advanced or metastatic hereditary or sporadic MTC. Documentation must be provided in subject’s medical chart.
- •4.Life expectancy of 12 weeks or longer
- •5.WHO Performance status 0-2
- •6.Able to swallow study medication
- •7.Presence of a measurable tumor as defined by:
- •a)a solitary lesion measuring =2 cm, OR
- •b)for multiple lesions, a sum of diameter =2cm (with no target lesion measuring <1cm and assuming 5 mm section), OR
- •c)for multiple lesions, a sum of diameter =3cm (with no target lesion measuring <1.5 cm assuming >5 mm section)
- •8.CTN = 500 pg/ml
- •9.All subjects (other than those with hereditary MTC who have a documented germline RET mutation) must submit a suitable archived tumor collection sample. If an archived tumor sample is not available prior to 2 weeks of randomization, a fresh tumor sample must be obtained in its place. The tumor sample must be obtained by the investigative site and shipped to its destination prior to randomization.
- •10.Negative pregnancy test for female subjects of childbearing potential
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
- •1.Provision of written informed consent
- •2.Female or male aged 18 years and over
- •3.Previously confirmed histological diagnosis of unresectable, locally advanced or metastatic hereditary or sporadic MTC. Documentation must be provided in subject’s medical chart.
- •4.Life expectancy of 12 weeks or longer
- •5.WHO Performance status 0-2
- •6.Able to swallow study medication
- •7.Presence of a measurable tumor as defined by:
- •a)a solitary lesion measuring =2 cm, OR
- •b)for multiple lesions, a sum of diameter =2cm (with no target lesion measuring <1cm and assuming 5 mm section), OR
- •c)for multiple lesions, a sum of diameter =3cm (with no target lesion measuring <1.5 cm assuming >5 mm section)
- •8.CTN = 500 pg/ml
- •9.All subjects (other than those with hereditary MTC who have a documented germline RET mutation) must submit a suitable archived tumor collection sample. If an archived tumor sample is not available prior to 2 weeks of randomization, a fresh tumor sample must be obtained in its place. The tumor sample must be obtained by the investigative site and shipped to its destination prior to randomization.
- •10.Negative pregnancy test for female subjects of childbearing potential
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1.Brain metastases or spinal cord compression, unless treated at least 4 weeks before first dose and stable without steroid treatment for 10 days
- •2.Any concomitant medications that may affect QTc or induce CYP3A4 function (with the exception of somatostatin or somatostatin analog) and/or any prohibited medications referenced in the protocol3.Major surgery within 4 weeks before randomization
- •4.The last dose of prior chemotherapy is received less than 4 weeks prior to randomization
- •5.Radiation therapy within the last 4 weeks prior to randomization (with the exception of palliative radiotherapy)
- •6.Serum bilirubin greater than 1.5 x the upper limit of reference range (ULRR)
- •7.Serum creatinine >1.5 x ULRR or creatinine clearance =50 ml/minute (calculated by Cockcroft-Gault formula)
- •8.Potassium <4.0 mmol/L despite supplementation; serum calcium (ionized or adjusted for albumin), or magnesium out of normal range despite supplementation
- •9.Alanine aminotransferase (ALT), aspartate aminotransferase (AST), or alkaline phosphatase (ALP) greater than 2.5 x ULRR, or greater than 5.0 x ULRR if judged by the investigator to be related to liver metastases
- •10.Significant cardiac event (eg myocardial infarction), superior vena cava [SVC] syndrome, New York Heart Association [NYHA] classification of heart disease =2 within 12 weeks before randomization, or presence of cardiac disease that in the opinion of the Investigator increases the risk of ventricular arrhythmia
- •11.History of arrhythmia (multifocal premature ventricular contractions [PVCs], bigeminy, trigeminy, ventricular tachycardia), which is symptomatic or requires treatment (CTCAE grade 3), symptomatic or uncontrolled atrial fibrillation despite treatment, or asymptomatic sustained ventricular tachycardia. Subjects with atrial fibrillation controlled by medication are permitted.
- •12.Congenital long QT syndrome or 1st degree relative with unexplained sudden death under 40 years of age
- •13.QT prolongation with other medications that required discontinuation of that medication
- •14.Presence of left bundle branch block (LBBB)
- •15.QTc with Bazett’s correction unmeasurable or =480 msec or greater on screening ECG (Note: If a subject has QTc interval =480 msec on screening ECG, the screening ECG may be repeated 2 times [at least 24 hours apart] for a total of 3 ECGs. The average QTc from the three screening ECGs must be <480 msec in order for the subject to be eligible for the study.)
- •16.Hypertension not controlled by medical therapy (systolic BP greater than 160 millimeter of mercury [mmHg] or diastolic blood pressure greater than 100 mmHg)
- •17.Previous or current malignancies of other histologies within the last 5 years, with the exception of tumors associated with MEN2a and MEN2b, in situ carcinoma of the cervix, and adequately treated basal cell or squamous cell carcinoma of the skin
- •18.Any unresolved chronic toxicity greater than CTCAE grade 2 from previous anticancer therapy
- •19.Participation in a clinical study and/or receipt of an investigational drug during the last 30 days (participation in the survival follow-up period of a study is not an exclusion)
- •20.Previous exposure to ZD6474
- •21.Currently pregnant or breast feeding
- •22.Involvement in the planning and conduct of the study (applies to both AstraZeneca staff or staff at the investigational site)
- •23.Previous randomization or treatment in the present study
- •1.Brain metastases or spinal cord compression, unless treated at least 4 weeks before first dose and stable without steroid treatment for 10 days
- •2.Any concomitant medications that may affect QTc or induce CYP3A4 function (with the exception of somatostatin or somatostatin analog) and/or any prohibited medications referenced in the protocol3.Major surgery within 4 weeks before randomization
- •4.The last dose of prior chemotherapy is received less than 4 weeks prior to randomization
- •5.Radiation therapy within the last 4 weeks prior to randomization (with the exception of palliative radiotherapy)
- •6.Serum bilirubin greater than 1.5 x the upper limit of reference range (ULRR)
- •7.Serum creatinine >1.5 x ULRR or creatinine clearance =50 ml/minute (calculated by Cockcroft-Gault formula)
- •8.Potassium <4.0 mmol/L despite supplementation; serum calcium (ionized or adjusted for albumin), or magnesium out of normal range despite supplementation
- •9.Alanine aminotransferase (ALT), aspartate aminotransferase (AST), or alkaline phosphatase (ALP) greater than 2.5 x ULRR, or greater than 5.0 x ULRR if judged by the investigator to be related to liver metastases
- •10.Significant cardiac event (eg myocardial infarction), superior vena cava [SVC] syndrome, New York Heart Association [NYHA] classification of heart disease =2 within 12 weeks before randomization, or presence of cardiac disease that in the opinion of the Investigator increases the risk of ventricular arrhythmia
- •11.History of arrhythmia (multifocal premature ventricular contractions [PVCs], bigeminy, trigeminy, ventricular tachycardia), which is symptomatic or requires treatment (CTCAE grade 3), symptomatic or uncontrolled atrial fibrillation despite treatment, or asymptomatic sustained ventricular tachycardia. Subjects with atrial fibrillation controlled by medication are permitted.
- •12.Congenital long QT syndrome or 1st degree relative with unexplained sudden death under 40 years of age
- •13.QT prolongation with other medications that required discontinuation of that medication
- •14.Presence of left bundle branch block (LBBB)
- •15.QTc with Bazett’s correction unmeasurable or =480 msec or greater on screening ECG (Note: If a subject has QTc interval =480 msec on screening ECG, the screening ECG may be repeated 2 times [at least 24 hours apart] for a total of 3 ECGs. The average QTc from the three screening ECGs must be <480 msec in order for the subject to be eligible for the study.)
- •16.Hypertension not controlled by medical therapy (systolic BP greater than 160 millimeter of mercury [mmHg] or diastolic blood pressure greater than 100 mmHg)
- •17.Previous or current malignancies of other histologies within the last 5 years, with the exception of tumors associated with MEN2a and MEN2b, in situ carcinoma of the cervix, and adequately treated basal cell or squamous cell carcinoma of the skin
- •18.Any unresolved chronic toxicity greater than CTCAE grade 2 from previous anticancer therapy
- •19.Participation in a clinical study and/or receipt of an investigational drug during the last 30 days (participation in the survival follow-up period of a study is not an exclusion)
- •20.Previous exposure to ZD6474
- •21.Currently pregnant or breast feeding
- •22.Involvement in the planning and conduct of the study (applies to both AstraZeneca staff or staff at the investigational site)
- •23.Previous randomization or treatment in the present study
研究者
相似试验
进行中（未招募）
不适用
An International, Phase II, Randomized, Double-Blinded, Placebo- Controlled, Multi-Center Study to Assess the Efficacy of ZD6474 ZACTIMA versus Placebo in Subjects with Unresectable Locally Advanced or Metastatic Medullary Thyroid Cancer - ZACTIMA 58EUCTR2005-005077-29-ITASTRAZENECA232
进行中（未招募）
不适用
An International, Phase II, Randomized, Double-Blinded, Placebo-Controlled, Multi-Center Study to Assess the Efficacy of ZD6474 (ZACTIMA ) versus Placebo in Subjects with Unresectable Locally Advanced or Metastatic Medullary Thyroid Cancer.Medullary thyroid cancerMedDRA version: 8.1Level: LLTClassification code 10027105Term: Medullary thyroid cancerEUCTR2005-005077-29-CZAstraZeneca AB232
招募中
2 期
A phase 2b, randomized, double-blind study of redasemtide (S-005151) in adult participants with acute ischemic strokePatient with acute ischemic strokeJPRN-jRCT2031230083Gomez Juan Carlos627
招募中
1 期
A phase 2b, randomized, double-blind study of redasemtide (S-005151) in adult participants with acute ischemic strokeacute ischemic strokeMedDRA version: 22.1Level: PTClassification code: 10061256Term: Ischaemic stroke Class: 100000004852CTIS2022-501890-38-00Shionogi B.V.524
进行中（未招募）
1 期
A Phase III, International, Randomised, Double-Blind, Parallel-Group, Multi-Centre Study to Assess the Efficacy of ZD6474(ZACTIMA™) Plus Best Supportive Care Versus Placebo Plus Best Supportive Care in Patients With Locally Advanced or Metastatic (Stage IIIB – IV) Non-Small Cell Lung Cancer (NSCLC) after Prior Therapy with an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor (EGFR TKI)on-small cell lung cancerEUCTR2006-002384-12-GBAstraZeneca AB1,140